Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.

Implication of all the available evidence This study shows that the Flexyn2a vaccine is well tolerated, immunogenic, and is protective against severe shigellosis, although protection against the per-protocol definition of shigellosis did not reach statistical significance.

also in 111,027 other papers